| Product Information | |
|---|---|
| Composition | Glimepiride IP 2 mg + Pioglitazone Hydrochloride IP 15 mg + Metformin Hydrochloride IP 500 mg (Bilayered) |
| Dosage Form | Tablet |
| Packing Size | 20 x 1 x 10 |
| Packing | Blister |
PYOSTAL GM 2 is a highly effective oral anti-diabetic medicine designed for the comprehensive management of Type 2 Diabetes Mellitus (T2DM). It combines the proven benefits of Glimepiride, Pioglitazone, and Metformin Hydrochloride in a single bilayered tablet, offering patients a convenient and synergistic approach to controlling blood glucose levels.
This triple therapy addresses insulin resistance, pancreatic insulin secretion, and hepatic glucose production, which are the three key defects in Type 2 Diabetes. By targeting multiple pathways, PYOSTAL GM 2 helps achieve better glycemic control, reduces the risk of diabetes-related complications, and improves overall metabolic health.
Belongs to the sulfonylurea class of drugs.
Stimulates the pancreas to secrete more insulin by acting on beta-cells.
Improves insulin utilization in peripheral tissues.
Helps in rapid reduction of post-meal blood glucose spikes.
Belongs to the thiazolidinedione class of anti-diabetic drugs.
Works by reducing insulin resistance in the muscles and adipose tissue.
Enhances the body’s response to insulin without increasing its production.
Improves lipid profile and reduces triglycerides, contributing to cardiovascular protection.
Belongs to the biguanide class of drugs.
Decreases hepatic glucose production and delays intestinal absorption of glucose.
Enhances peripheral glucose uptake and utilization.
Considered a first-line therapy for Type 2 Diabetes due to its safety and effectiveness.
The combination of Glimepiride, Pioglitazone, and Metformin ensures a triple-action mechanism:
Increases Insulin Secretion:
Glimepiride stimulates pancreatic beta cells to release insulin.
Enhances Insulin Sensitivity:
Pioglitazone reduces insulin resistance in muscles and adipose tissue, enabling cells to respond better to insulin.
Reduces Hepatic Glucose Output:
Metformin decreases glucose production in the liver, ensuring fasting blood sugar remains under control.
Together, these mechanisms provide comprehensive glycemic control by targeting fasting plasma glucose (FPG), postprandial glucose (PPG), and HbA1c levels.
Triple therapy in one tablet – convenient dosing and better patient compliance.
Provides effective blood glucose control in patients not adequately managed with dual therapy.
Reduces insulin resistance and improves insulin secretion.
Helps in lowering HbA1c levels significantly.
Contributes to long-term cardiovascular and metabolic health.
Lowers the risk of microvascular complications like neuropathy, nephropathy, and retinopathy.
Improves overall quality of life for diabetic patients.
PYOSTAL GM 2 is indicated for:
Type 2 Diabetes Mellitus patients who are inadequately controlled with lifestyle modifications and monotherapy/dual therapy.
Adults requiring combination therapy to manage uncontrolled blood sugar levels.
Patients with a high risk of diabetes-related complications requiring multi-targeted treatment.
The usual dosage is as prescribed by the physician, depending on patient condition and response.
PYOSTAL GM 2 should be taken with meals to reduce the risk of gastrointestinal side effects.
Regular monitoring of blood glucose levels, HbA1c, liver function, and renal function is recommended during therapy.
Not recommended for Type 1 Diabetes Mellitus or Diabetic Ketoacidosis (DKA).
Should be used with caution in patients with renal or hepatic impairment.
Pioglitazone may cause fluid retention; avoid use in patients with congestive heart failure.
Risk of hypoglycemia exists, particularly if taken with other anti-diabetic agents.
Alcohol consumption should be avoided to reduce the risk of lactic acidosis associated with Metformin.
Pregnant and lactating women should use this medicine only if clearly prescribed by the physician.
Like all medicines, PYOSTAL GM 2 may cause some side effects, although not everyone experiences them. Common side effects include:
Hypoglycemia (low blood sugar)
Nausea, vomiting, or diarrhea
Weight gain (due to Pioglitazone)
Edema or fluid retention
Dizziness or headache
Gastrointestinal discomfort
Most side effects are mild and can be managed with supportive care and proper monitoring. Consult your physician if side effects persist.
Can interact with other anti-diabetic agents, antihypertensives, corticosteroids, and diuretics.
Patients should inform their doctor about all medications, supplements, or herbal products they are using before starting PYOSTAL GM 2.
Store in a cool and dry place, away from direct sunlight.
Keep out of reach of children.
Do not use the medicine after the expiry date printed on the pack.
Combines three well-established anti-diabetic medicines in one convenient bilayered tablet.
Provides comprehensive control of fasting, postprandial, and overall glycemic levels.
Improves patient adherence by reducing the number of tablets required daily.
Manufactured under strict quality standards, ensuring safety and effectiveness.
PYOSTAL GM 2 (Glimepiride 2 mg + Pioglitazone Hydrochloride 15 mg + Metformin Hydrochloride 500 mg) is an advanced anti-diabetic formulation that addresses the multiple defects involved in Type 2 Diabetes Mellitus. Its unique triple-drug combination provides superior control over blood glucose levels, reduces the risk of complications, and enhances patient outcomes.
By targeting insulin secretion, insulin sensitivity, and hepatic glucose production simultaneously, PYOSTAL GM 2 is a reliable solution for patients needing multi-targeted diabetes management. With proper medical supervision, diet, exercise, and regular monitoring, it plays a vital role in improving the quality of life for diabetic patients.
